Skip to content

A Clinical Study on Zi Shui Qing Gan Yin for the Treatment of Patients with Functional Dyspepsia of GanWei Yu Re Syndrome

A Clinical Study on Zishui Qinggan Yin in the Treatment of Functional Dyspepsia Patients with GanWei Yu Re Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000850
Enrollment
Unknown
Registered
2026-04-01
Start date
2024-09-18
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Dyspepsia

Interventions

the conventional-dose Zishui Qinggan Yin group:Take "Zi Shui Qing Gan Yin" Chinese herbal decoction granules half an hour before breakfast and dinner daily, one packet per dose, twice daily.
Zishui Qingshen Yin low-dose group:Take "Zi Shui Qing Gan Yin" Chinese herbal decoction granules half an hour before breakfast and dinner each day, 1/2 packet each time, twice daily.
Western medicine combination therapy control group:Take one tablet of flupentixol and melitracen (Deplirin) before breakfast, once daily
take one tablet of mosapride citrate dispersible tablets (Xinluona) before lunch and dinner, respectively.

Sponsors

Shanxi Provincial Hospital of Traditional Chinese Medicine (Shanxi Academy of Traditional Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria for functional dyspepsia in Western medicine and are identified as having GanWei Yu Re Syndrome in Chinese medicine pattern identification. 2. Patients aged between 18 and 70 years (including 18 and 70 years old). 3. Patients who have not used any disease-related treatment drugs within the past 2 weeks prior to enrollment. 4. Patients who have given informed consent for this study and voluntarily agree to participate in the clinical observation.

Exclusion criteria

Exclusion criteria: 1.Pregnant or breastfeeding women, and individuals with mental disorders. 2.Patients with allergic constitutions or a history of allergy to multiple medications. 3.Patients with severe organic lesions in major organs such as the heart, liver, kidneys, endocrine system, or hematopoietic system. 4.Patients with severe mental or psychological disorders, such as schizophrenia, personality disorders, or suicidal tendencies. 5.Patients who are unable to comply with the research protocol or have poor adherence to treatment.

Design outcomes

Primary

MeasureTime frame
The degree of improvement in the patient's clinical symptoms.;The degree of improvement in patients' anxiety and depression states.;

Secondary

MeasureTime frame
The degree of change in patients' serum motilin (MTL), ghrelin (GRL), and 5-hydroxytryptamine (5-HT) indicators.;

Countries

China

Contacts

Public ContactLv Xiaoyan

Shanxi Provincial Hospital of Traditional Chinese Medicine (Shanxi Academy of Traditional Chinese Medicine)

1270929351@qq.com15234175985

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026